Fresh Tracks Therapeutics reports GAAP EPS of -$2.07, revenue of $0.49M
Nov. 10, 2022 4:23 PM ETFresh Tracks Therapeutics, Inc. (FRTX)By: SA News Team
- Fresh Tracks Therapeutics press release (NASDAQ:FRTX): Q3 GAAP EPS of -$2.07.
- Revenue of $0.49M (+276.9% Y/Y).
- The company reported cash and cash equivalents of $11.3M as of Sep. 30, 2022, compared to $26.9M as of Dec. 31, 2021.